UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2002 ---------------- (Date of Report) ENTROPIN, INC. -------------- (Exact name of registrant as specified in its charter) Colorado 33-23693 84-1090424 - ---------------------------- ------------ ------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 45926 Oasis Street, Indio, California 92201 ------------------------------------------- (Address of principal executive offices, including zip code) (760) 775-8333 -------------- (Registrant's telephone number, including area code) N/A ---- (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS. - --------------------- Entropin, Inc. ("Entropin") issued the following press release on January 3, 2002: ENTROPIN LAUNCHES NEW WEBSITE ENHANCED INFORMATION PROVIDED TO INVESTORS INDIO, Calif. (January 3, 2002) - Entropin, Inc. (Nasdaq: ETOP, ETOPW) is a specialty pharmaceutical company developing new topical therapeutics for painful soft tissue injuries and diseases. Today, the Company announced the launch of its redesigned web site, accessible at http://www.entropin.com. The redesigned site provides visitors with updated information about the Company, Esterom(R), its revolutionary new drug, the market for Esterom(R), and an enhanced investor center feature. The updated site also offers new options for receiving future information about Entropin, Inc. Please visit www.entropin.com and click on "Inside Edge Team". Even if you are a current "Inside Edge Team" member, please visit this section to update your information and explore the options for receiving information on Esterom(R), and Entropin, Inc. ABOUT ENTROPIN Entropin, Inc. is a pharmaceutical research and development company, initially focused on the development of Esterom(R), a novel topical therapeutic for the treatment of painful soft tissue injuries, such as tendonitis or back sprain, that result in impaired function. # # # SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 10, 2002 ENTROPIN, INC By: /s/ THOMAS G. TACHOVSKY ----------------------------------- Thomas G. Tachovsky President and Chief Executive Officer